Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.
Very undervalued with adequate balance sheet.
Share Price & News
How has Jazz Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: JAZZ has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: JAZZ underperformed the US Pharmaceuticals industry which returned 3.7% over the past year.
Return vs Market: JAZZ underperformed the US Market which returned 14% over the past year.
Price Volatility Vs. Market
How volatile is Jazz Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StImagine Owning Jazz Pharmaceuticals (NASDAQ:JAZZ) And Wondering If The 20% Share Price Slide Is Justified
3 weeks ago | Simply Wall StIs Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Excessively Paying Its CEO?
1 month ago | Simply Wall StIf You Like EPS Growth Then Check Out Jazz Pharmaceuticals (NASDAQ:JAZZ) Before It's Too Late
Is Jazz Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: JAZZ ($130.86) is trading below our estimate of fair value ($348.78)
Significantly Below Fair Value: JAZZ is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: JAZZ is good value based on its PE Ratio (12.4x) compared to the Pharmaceuticals industry average (21.3x).
PE vs Market: JAZZ is good value based on its PE Ratio (12.4x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: JAZZ is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: JAZZ is good value based on its PB Ratio (2.4x) compared to the US Pharmaceuticals industry average (2.9x).
How is Jazz Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JAZZ's forecast earnings growth (15.2% per year) is above the savings rate (1.7%).
Earnings vs Market: JAZZ's earnings (15.2% per year) are forecast to grow faster than the US market (13.1% per year).
High Growth Earnings: JAZZ's earnings are forecast to grow, but not significantly.
Revenue vs Market: JAZZ's revenue (3.7% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: JAZZ's revenue (3.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: JAZZ's Return on Equity is forecast to be high in 3 years time (22.4%)
How has Jazz Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: JAZZ has a large one-off loss of $168.2M impacting its September 30 2019 financial results.
Growing Profit Margin: JAZZ's current net profit margins (29.6%) are higher than last year (28.1%).
Past Earnings Growth Analysis
Earnings Trend: JAZZ's earnings have grown significantly by 23.4% per year over the past 5 years.
Accelerating Growth: JAZZ's earnings growth over the past year (17.1%) is below its 5-year average (23.4% per year).
Earnings vs Industry: JAZZ earnings growth over the past year (17.1%) exceeded the Pharmaceuticals industry 2.4%.
Return on Equity
High ROE: JAZZ's Return on Equity (19.9%) is considered low.
Return on Assets
Return on Capital Employed
How is Jazz Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: JAZZ's short term assets ($1.5B) exceed its short term liabilities ($390.4M).
Long Term Liabilities: JAZZ's short term assets ($1.5B) do not cover its long term liabilities ($2.1B).
Debt to Equity History and Analysis
Debt Level: JAZZ's debt to equity ratio (52.6%) is considered high.
Reducing Debt: JAZZ's debt to equity ratio has reduced from 100% to 52.6% over the past 5 years.
Debt Coverage: JAZZ's debt is well covered by operating cash flow (56.4%).
Interest Coverage: JAZZ's interest payments on its debt are well covered by EBIT (11.5x coverage).
Inventory Level: JAZZ has a low level of unsold assets or inventory.
Debt Coverage by Assets: JAZZ's debt is not covered by short term assets (assets are 0.9x debt).
What is Jazz Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate JAZZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate JAZZ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JAZZ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JAZZ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of JAZZ's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bruce Cozadd (55yo)
Mr. Bruce C. Cozadd co-founded Jazz Pharmaceuticals Public Limited Company (also known as Jazzpharmaceuticals, Inc.) in 2003 and has been Chairman and Chief Executive Officer since April 2009. Mr. Cozadd s ...
CEO Compensation Analysis
Compensation vs Market: Bruce's total compensation ($USD11.44M) is above average for companies of similar size in the US market ($USD6.39M).
Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.
|President & COO||2.1yrs||US$5.75m||0.011% $801.8k|
|Executive Vice President of US Commercial||5.8yrs||US$2.86m||0.011% $840.3k|
|Senior VP of Finance & Principal Accounting Officer||8.1yrs||US$1.24m||0.018% $1.3m|
|Senior Vice President of Technical Operations||0.3yrs||no data||0.0038% $281.3k|
|Vice President of Investor Relations||0yrs||no data||no data|
|Senior VP & General Counsel||0.6yrs||no data||no data|
|Senior VP & Chief Human Resources Officer||1.3yrs||no data||no data|
|Senior Vice President of Sleep & CNS Medicine||0yrs||no data||no data|
Experienced Management: JAZZ's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
|Independent Director||16.1yrs||US$546.92k||0.014% $1.1m|
|Independent Director||8.1yrs||US$554.42k||1.95% $144.1m|
|Independent Director||6.8yrs||US$569.42k||0.013% $967.6k|
|Independent Director||6.8yrs||US$566.92k||0.010% $754.4k|
|Independent Director||10.6yrs||US$559.42k||0.028% $2.1m|
|Independent Director||10.1yrs||US$544.42k||0.011% $791.4k|
|Lead Independent Director||5.8yrs||US$591.92k||0.0044% $328.0k|
|Independent Director||7.6yrs||US$554.42k||0.012% $906.9k|
|Independent Director||6.8yrs||US$579.42k||0.012% $878.7k|
Experienced Board: JAZZ's board of directors are considered experienced (7.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: JAZZ insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Jazz Pharmaceuticals plc's company bio, employee growth, exchange listings and data sources
- Name: Jazz Pharmaceuticals plc
- Ticker: JAZZ
- Exchange: NasdaqGS
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.403b
- Shares outstanding: 56.57m
- Website: https://www.jazzpharma.com
Number of Employees
- Jazz Pharmaceuticals plc
- Waterloo Exchange
- Fifth Floor
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|JAZZ||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 2007|
|J7Z||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2007|
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also develops Solriamfetol for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea, as well as in Phase II clinical trial for EDS associated with Parkinson’s disease; Vyxeos for acute myeloid leukemia; and JZP-258 to treat EDS and cataplexy with narcolepsy and potential treatment of idiopathic hypersomnia and a chronic neurological disorder. In addition, it sells psychiatry and other products. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; and XL-protein GmbH. The company is headquartered in Dublin, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/26 00:50|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.